SCHEMBL30196055

SCHEMBL30196055

CCOc1ccc(-c2ccccc2)cc1OC

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.54
KDM4E B2RXH2 4/20 0.54
GAA P10253 1/20 0.54
TSHR P16473 1/20 0.54
NPC1 O15118 5/20 0.52
RAB9A P51151 4/20 0.52
HSD17B10 Q99714 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
FPR2 P25090 1/20 0.52
ALDH1A1 P00352 3/20 0.50
KMT2A Q03164 3/20 0.50
MAPK1 P28482 3/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
HPGD P15428 2/20 0.50
MEN1 O00255 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
POLB P06746 1/20 0.50
LMNA P02545 1/20 0.50
ALOX12 P18054 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30196061 0.93 KDM4E (0.52) MAPTKDM4ENPC1RAB9AHSD17B10
SCHEMBL27814160 0.91 KDM4E (0.60) MAPTKDM4ENPC1RAB9AHSD17B10
SCHEMBL27509557 0.85 PDE4A (0.50) MAPTKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL4533772 0.85 L3MBTL1 (0.62) MAPTKDM4ETSHRNPC1RAB9A
SCHEMBL12303132 0.83 KDM4E (0.60) MAPTKDM4ETSHRNPC1RAB9A
SCHEMBL1778039 0.80 HSD17B10 (0.65) MAPTKDM4EGAANPC1RAB9A
SCHEMBL5255563 0.80 MAOA (0.49) MAPTKDM4ETSHRNPC1RAB9A
SCHEMBL1911874 0.80 MRGPRX4 (0.54) MAPTKDM4EGAANPC1RAB9A
SCHEMBL27324840 0.80 EGFR (0.56) MAPTKDM4ENPC1RAB9AHSD17B10
SCHEMBL12500710 0.79 S1PR1 (0.59) MAPTKDM4EGAANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230148402-A1 Boron Containing PDE4 Inhibitors PFIZER INC. (US) 2023-05-11 US disclosed
US-11559538-B2 Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors PFIZER INC. (US) 2023-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11559538-B2 Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors PDE4B, PDE4A, PDE3B MAPT 3874/4885KDM4E 406/4885GAA 208/4885
US-20230148402-A1 Boron Containing PDE4 Inhibitors PDE4B, PDE4A, PDE3B MAPT 3172/4885KDM4E 406/4885GAA 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.